Periodic Reporting for period 1 - Tydo-Stimulant (An Effective Microwave-Assisted Extraction Process for a Natural Biostimulant Blend)
Período documentado: 2019-02-01 hasta 2019-05-31
As the concerns about the environmental consequences of using chemical-based fertilisers on crops arise, there is need for products that enhance crop’s health and productivity without affecting the environment. In response to this issue, Tydock Pharma has developed and protected a unique and innovative green microwave assisted process that turns beeswax into a potent plant biostimulant which contains policosanols, including triacontanol (TRIA) and octacosanol, as active compounds. Our product, Tydo-Stimulant, has demonstrated an outstanding performance in increasing root and leaf volumes, increasing crop yields, reducing stress and boosting the metabolism on different cultivars.
By bringing this product to the market, Tydock Pharma will offer a high-quality effective product that has not negative impacts neither on the environment nor on human health.
Our main objective is to reach TRL9 and launch our product in the European market.
By bringing this product to the market, Tydock Pharma will offer a high-quality effective product that has not negative impacts neither on the environment nor on human health.
Our main objective is to reach TRL9 and launch our product in the European market.
We have brought our process to TRL7. At present, we have the capability to produce 900 tonnes of final liquid product ready to apply on crops.
We have defined our commercialization strategy: initially B2B on five European countries (Italy, Spain, France, Germany and Belgium) and subsequently B2C on more countries. We also have confirmed our freedom to operate, started informal conversations with potential distributors, and signed pre-commercialization agreements with three early adopters: Zero Srl, Licopharma Srl and Cluster Nanotech Lab Ltd.
We have updated our business plan, made financial projections for the next 5 years and defined the working plans to reach TRL9 by 2021. These are upscaling of the process, upscaling of the product, efficacy pilots, certification, project management, exploitation and dissemination.
We have defined our commercialization strategy: initially B2B on five European countries (Italy, Spain, France, Germany and Belgium) and subsequently B2C on more countries. We also have confirmed our freedom to operate, started informal conversations with potential distributors, and signed pre-commercialization agreements with three early adopters: Zero Srl, Licopharma Srl and Cluster Nanotech Lab Ltd.
We have updated our business plan, made financial projections for the next 5 years and defined the working plans to reach TRL9 by 2021. These are upscaling of the process, upscaling of the product, efficacy pilots, certification, project management, exploitation and dissemination.
To date, methods of policosanols and TRIA extraction encompass long processes and return low levels of TRIA. Thus, companies struggle to produce TRIA from natural sources in large quantities and at reasonable costs, making widespread adoption very difficult. Furthermore, current extraction methods involve toxic solvents that result in environmentally unfriendly residues and contaminated biostimulant products.
In addition, our in house trials have shown outstanding effects of our product on different crops.
Therefore, Tydock Pharma’s process is greener, more efficient and enables to produce a higher quality residue-free biostimulant product than our competitors at a very competitive price
In addition, our in house trials have shown outstanding effects of our product on different crops.
Therefore, Tydock Pharma’s process is greener, more efficient and enables to produce a higher quality residue-free biostimulant product than our competitors at a very competitive price